The
Food and Drug Administration removed its full clinical hold on Geron Corp.'s
(Nasdaq: GERN) investigational new drug application for imetelstat sending the stock price soaring 63 cents to $2.86.
Clinical hold removed on Geron's imetelstat
November 03, 2014 at 12:08 PM EST
